Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Icahn School of Medicine at Mount Sinai
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
Roche Pharma AG
QIAGEN Marseille
Information provided by (Responsible Party):
Ronald Hoffman, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01259856
First received: December 7, 2010
Last updated: June 4, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2024
  Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)